# BIOXYTRAN, INC

BIOXYTRAN, INC is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** bioxytraninc.com

## Regulatory record

- **Reports private funds:** No

## About

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

## Sectors

- Drug Development & Pharma Tech

## People

- David Platt — Chief Executive Officer
- Michael Sheikh — Chief Financial Officer

## Questions

### What is Bioxytran's lead drug candidate?

The lead asset is BXT-25, a brain-tropic oxygen carrier designed to treat acute ischemic stroke by transporting oxygen across the blood-brain barrier. The firm has also explored additional applications for its carbohydrate-based platform in wound care and antiviral indications.

### How is Bioxytran funded as a clinical-stage company?

Bioxytran does not operate with a traditional venture capital backing. It has remained publicly traded on OTC markets and raises capital through equity financings and convertible instruments, making its financial structure atypical for a pre-revenue biotech.

### Does Bioxytran have any partnership with major pharmaceutical companies?

There is no public record of a partnership with a major pharmaceutical firm. Bioxytran's disclosed collaborations have primarily involved contract research organizations and academic institutions for its clinical and preclinical work.

## Related profiles

- [AIM ImmunoTech Inc.](https://altss.com/profile/aim-immunotech-inc)
- [GRI Bio, Inc.](https://altss.com/profile/gri-bio-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/bioxytran-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology